HLA-A2-restricted epitopes have been identified from MAGE-C1, and specific CD8+ T cells were able to recognize MAGE-C1 expressing myeloma cells [31], which may facilitate development of immunotherapy targeting MAGE-C1. This evidence concerns the gene CD8A and plasma cell myeloma.